DAVID A CLARK
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
- Where
- SPRINGFIELD, OR
- NPI
- 1578760278
- Received
- $1,083,327 in 1,467 records, 2019 to 2025 ($1,083,252 general, $75 research)
- As principal investigator
- $89,992 of research payments to others in 37 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 321 | $267,411 |
| 2024 | General payment | 227 | $188,650 |
| 2023 | General payment | 180 | $106,579 |
| 2022 | General payment | 180 | $120,040 |
| 2021 | General payment | 169 | $121,777 |
| 2020 | General payment | 117 | $87,986 |
| 2019 | General payment | 272 | $190,807 |
| 2019 | Research payment | 1 | $75 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 336 | $893,759 |
| Travel and Lodging | 328 | $95,630 |
| Consulting Fee | 39 | $65,087 |
| Food and Beverage | 748 | $22,610 |
| Honoraria | 1 | $5,460 |
| Education | 14 | $704 |
| Research payment | 1 | $75 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Janssen Biotech, Inc. | $281 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Amgen Inc. | $166 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Janssen Biotech, Inc. | $38 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Janssen Biotech, Inc. | $29 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Janssen Biotech, Inc. | $26 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-12-22 | Amgen Inc. | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-17 | Amgen Inc. | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-17 | Amgen Inc. | $79 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-12-16 | UCB, Inc. | $1,593 | Travel and Lodging | In-kind items and services | Zilbrysq Drug, Neurology | 2025 | |
| 2025-12-15 | UCB, Inc. | $20 | Travel and Lodging | In-kind items and services | Zilbrysq Drug, Neurology | 2025 | |
| 2025-12-12 | TG Therapeutics, Inc. | $26 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-12-11 | Amgen Inc. | $96 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-11 | ARGENX US, INC. | $16 | Food and Beverage | In-kind items and services | VYVGART HYTRULO Drug, Neurology | 2025 | |
| 2025-12-08 | TG Therapeutics, Inc. | $3,712 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-12-06 | Janssen Biotech, Inc. | $3,885 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-06 | Janssen Biotech, Inc. | $3,885 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-06 | Janssen Biotech, Inc. | $1,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-04 | ARGENX US, INC. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-12-03 | Janssen Biotech, Inc. | $256 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-12-03 | Janssen Biotech, Inc. | $223 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-12-02 | Janssen Biotech, Inc. | $138 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-01 | Amgen Inc. | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-25 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-11-20 | ARGENX US, INC. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-11-20 | Amgen Inc. | $64 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-19 | UCB, Inc. | $1,680 | Consulting Fee | Cash or cash equivalent | Rystiggo Drug, Neurology | 2025 | |
| 2025-11-19 | UCB, Inc. | $91 | Travel and Lodging | Cash or cash equivalent | Rystiggo Drug, Neurology | 2025 | |
| 2025-11-19 | UCB, Inc. | $51 | Travel and Lodging | Cash or cash equivalent | Rystiggo Drug, Neurology | 2025 | |
| 2025-11-19 | UCB, Inc. | $19 | Travel and Lodging | Cash or cash equivalent | Rystiggo Drug, Neurology | 2025 | |
| 2025-11-12 | Amgen Inc. | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-12 | TG Therapeutics, Inc. | $465 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-11-11 | JAZZ PHARMACEUTICALS INC. | $27 | Food and Beverage | In-kind items and services | EPIDIOLEX Drug, NEUROLOGY | 2025 | |
| 2025-11-08 | Janssen Biotech, Inc. | $3,885 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-08 | Janssen Biotech, Inc. | $1,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-08 | Janssen Biotech, Inc. | $1,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-06 | UCB, Inc. | $1,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2025 | |
| 2025-11-06 | Janssen Biotech, Inc. | $154 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-06 | Janssen Biotech, Inc. | $150 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-04 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-10-29 | TG Therapeutics, Inc. | $3,712 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-10-29 | TG Therapeutics, Inc. | $79 | Travel and Lodging | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-10-29 | TG Therapeutics, Inc. | $23 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-10-28 | UCB, Inc. | $150 | Food and Beverage | In-kind items and services | Rystiggo Drug, Neurology | 2025 | |
| 2025-10-28 | UCB, Inc. | $49 | Food and Beverage | In-kind items and services | Rystiggo Drug, Neurology | 2025 | |
| 2025-10-28 | UCB, Inc. | $25 | Food and Beverage | In-kind items and services | Rystiggo Drug, Neurology | 2025 | |
| 2025-10-28 | UCB, Inc. | $25 | Food and Beverage | In-kind items and services | Rystiggo Drug, Neurology | 2025 | |
| 2025-10-28 | ARGENX US, INC. | $14 | Food and Beverage | In-kind items and services | VYVGART HYTRULO Drug, Neurology | 2025 | |
| 2025-10-25 | Janssen Biotech, Inc. | $3,885 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-23 | UCB, Inc. | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Rystiggo Drug, Neurology | 2025 | |
| 2025-10-23 | Janssen Biotech, Inc. | $1,049 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-23 | Janssen Biotech, Inc. | $587 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-23 | UCB, Inc. | $245 | Travel and Lodging | Cash or cash equivalent | Rystiggo Drug, Neurology | 2025 | |
| 2025-10-23 | Janssen Biotech, Inc. | $169 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-23 | Janssen Biotech, Inc. | $144 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-23 | TG Therapeutics, Inc. | $30 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-10-22 | GENZYME CORPORATION | $20 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-20 | TG Therapeutics, Inc. | $4,387 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-10-20 | TG Therapeutics, Inc. | $235 | Travel and Lodging | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-10-15 | TG Therapeutics, Inc. | $3,712 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-10-15 | TG Therapeutics, Inc. | $110 | Travel and Lodging | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-10-11 | Janssen Biotech, Inc. | $1,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-07 | Janssen Biotech, Inc. | $25 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-10-07 | Janssen Biotech, Inc. | $19 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-10-06 | Janssen Biotech, Inc. | $26 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-10-06 | Janssen Biotech, Inc. | $25 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-10-04 | Janssen Biotech, Inc. | $3,885 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-02 | Janssen Biotech, Inc. | $989 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-02 | Janssen Biotech, Inc. | $453 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-02 | Janssen Biotech, Inc. | $211 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-02 | Janssen Biotech, Inc. | $149 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-01 | TG Therapeutics, Inc. | $4,387 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-10-01 | TG Therapeutics, Inc. | $163 | Travel and Lodging | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-09-30 | UCB, Inc. | $140 | Food and Beverage | In-kind items and services | Rystiggo Drug, Neurology | 2025 | |
| 2025-09-25 | UCB, Inc. | $303 | Travel and Lodging | In-kind items and services | Rystiggo Drug, Neurology | 2025 | |
| 2025-09-25 | Amgen Inc. | $17 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-09-23 | UCB, Inc. | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Rystiggo Drug, Neurology | 2025 | |
| 2025-09-18 | TG Therapeutics, Inc. | $4,387 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-09-18 | TG Therapeutics, Inc. | $193 | Travel and Lodging | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-09-18 | TG Therapeutics, Inc. | $83 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-09-13 | Janssen Biotech, Inc. | $3,885 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-09-11 | Janssen Biotech, Inc. | $835 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-11 | UCB, Inc. | $784 | Travel and Lodging | In-kind items and services | Rystiggo Drug, Neurology | 2025 | |
| 2025-09-11 | Janssen Biotech, Inc. | $653 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-11 | Janssen Biotech, Inc. | $133 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-11 | Janssen Biotech, Inc. | $127 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-10 | TG Therapeutics, Inc. | $232 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-09-10 | Lundbeck LLC | $15 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2025 | |
| 2025-09-09 | UCB, Inc. | $4,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2025 | |
| 2025-09-09 | UCB, Inc. | $1,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Rystiggo Drug, Neurology | 2025 | |
| 2025-09-09 | UCB, Inc. | $77 | Travel and Lodging | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2025 | |
| 2025-09-09 | UCB, Inc. | $74 | Travel and Lodging | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2025 | |
| 2025-09-09 | TG Therapeutics, Inc. | $18 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-09-08 | UCB, Inc. | $15 | Travel and Lodging | In-kind items and services | Rystiggo Drug, Neurology | 2025 | |
| 2025-09-02 | ARGENX US, INC. | $18 | Food and Beverage | In-kind items and services | VYVGART HYTRULO Drug, Neurology | 2025 | |
| 2025-09-02 | ARGENX US, INC. | $1 | Food and Beverage | In-kind items and services | VYVGART HYTRULO Drug, Neurology | 2025 | |
| 2025-08-28 | UCB, Inc. | $187 | Travel and Lodging | In-kind items and services | Zilbrysq Drug, Neurology | 2025 | |
| 2025-08-28 | UCB, Inc. | $125 | Food and Beverage | In-kind items and services | Zilbrysq Drug, Neurology | 2025 | |
| 2025-08-27 | UCB, Inc. | $204 | Travel and Lodging | In-kind items and services | Zilbrysq Drug, Neurology | 2025 | |
| 2025-08-25 | Janssen Biotech, Inc. | $13 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-22 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-08-21 | TG Therapeutics, Inc. | $1,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-08-21 | TG Therapeutics, Inc. | $460 | Travel and Lodging | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-08-20 | Amgen Inc. | $687 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-08-19 | UCB, Inc. | $17 | Food and Beverage | In-kind items and services | Rystiggo Drug, Neurology | 2025 | |
| 2025-08-11 | Biogen, Inc. | $343 | Consulting Fee | Cash or cash equivalent | TYSABRI Biological, Neurology | 2025 | |
| 2025-08-11 | TG Therapeutics, Inc. | $17 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-08-08 | Alexion Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-08-05 | UCB, Inc. | $200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2025 | |
| 2025-08-04 | Vanda Pharmaceuticals Inc. | $2,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-08-04 | Biogen, Inc. | $685 | Consulting Fee | Cash or cash equivalent | VUMERITY Drug, Neurology | 2025 | |
| 2025-08-04 | Vanda Pharmaceuticals Inc. | $102 | Travel and Lodging | Cash or cash equivalent | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-08-04 | Vanda Pharmaceuticals Inc. | $23 | Food and Beverage | Cash or cash equivalent | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-08-04 | Vanda Pharmaceuticals Inc. | $6 | Food and Beverage | Cash or cash equivalent | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-07-30 | GENZYME CORPORATION | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-29 | Vanda Pharmaceuticals Inc. | $22 | Food and Beverage | In-kind items and services | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-07-24 | ARGENX US, INC. | $751 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-07-24 | ARGENX US, INC. | $563 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-07-24 | ARGENX US, INC. | $488 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-07-24 | ARGENX US, INC. | $40 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-07-24 | ARGENX US, INC. | $20 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-07-22 | TG Therapeutics, Inc. | $5,737 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-07-22 | UCB, Inc. | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Rystiggo Drug, Neurology | 2025 | |
| 2025-07-22 | UCB, Inc. | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Rystiggo Drug, Neurology | 2025 | |
| 2025-07-22 | Biogen, Inc. | $2,740 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TYSABRI Biological, Neurology | 2025 | |
| 2025-07-22 | Biogen, Inc. | $1,558 | Travel and Lodging | In-kind items and services | VUMERITY Drug, Neurology | 2025 | |
| 2025-07-22 | Biogen, Inc. | $436 | Travel and Lodging | In-kind items and services | VUMERITY Drug, Neurology | 2025 | |
| 2025-07-22 | UCB, Inc. | $226 | Travel and Lodging | Cash or cash equivalent | Rystiggo Drug, Neurology | 2025 | |
| 2025-07-22 | UCB, Inc. | $169 | Travel and Lodging | Cash or cash equivalent | Rystiggo Drug, Neurology | 2025 | |
| 2025-07-22 | Biogen, Inc. | $27 | Food and Beverage | Cash or cash equivalent | VUMERITY Drug, Neurology | 2025 | |
| 2025-07-22 | Biogen, Inc. | $19 | Food and Beverage | Cash or cash equivalent | VUMERITY Drug, Neurology | 2025 | |
| 2025-07-22 | UCB, Inc. | $6 | Food and Beverage | Cash or cash equivalent | Rystiggo Drug, Neurology | 2025 | |
| 2025-07-22 | UCB, Inc. | $4 | Food and Beverage | Cash or cash equivalent | Rystiggo Drug, Neurology | 2025 | |
| 2025-07-21 | Biogen, Inc. | $7,535 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VUMERITY Drug, Neurology | 2025 | |
| 2025-07-21 | Biogen, Inc. | $436 | Travel and Lodging | In-kind items and services | VUMERITY Drug, Neurology | 2025 | |
| 2025-07-21 | Biogen, Inc. | $57 | Travel and Lodging | Cash or cash equivalent | VUMERITY Drug, Neurology | 2025 | |
| 2025-07-21 | Biogen, Inc. | $39 | Food and Beverage | Cash or cash equivalent | VUMERITY Drug, Neurology | 2025 | |
| 2025-07-17 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-07-16 | Janssen Biotech, Inc. | $38 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-07-16 | Janssen Biotech, Inc. | $38 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-07-16 | Janssen Biotech, Inc. | $21 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-07-16 | ARGENX US, INC. | $14 | Food and Beverage | In-kind items and services | VYVGART HYTRULO Drug, Neurology | 2025 | |
| 2025-07-16 | ARGENX US, INC. | $4 | Food and Beverage | In-kind items and services | VYVGART HYTRULO Drug, Neurology | 2025 | |
| 2025-07-15 | Amgen Inc. | $3,850 | Consulting Fee | Cash or cash equivalent | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-07-15 | Amgen Inc. | $2,750 | Consulting Fee | Cash or cash equivalent | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-07-14 | UCB, Inc. | $40 | Travel and Lodging | In-kind items and services | Zilbrysq Drug, Neurology | 2025 | |
| 2025-07-12 | Janssen Biotech, Inc. | $3,885 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-07-10 | ARGENX US, INC. | $4,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-07-10 | ABBVIE INC. | $3,675 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-07-10 | ARGENX US, INC. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-07-10 | ARGENX US, INC. | $245 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-07-10 | ARGENX US, INC. | $81 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-07-10 | UCB, Inc. | $19 | Food and Beverage | In-kind items and services | Rystiggo Drug, Neurology | 2025 | |
| 2025-07-10 | ARGENX US, INC. | $19 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-07-10 | ARGENX US, INC. | $8 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-07-10 | ARGENX US, INC. | $7 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2025 | |
| 2025-07-08 | UCB, Inc. | $31 | Food and Beverage | In-kind items and services | Rystiggo Drug, Neurology | 2025 | |
| 2025-07-01 | Amgen Inc. | $43 | Food and Beverage | Cash or cash equivalent | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-07-01 | Amgen Inc. | $38 | Travel and Lodging | Cash or cash equivalent | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-06-28 | Janssen Biotech, Inc. | $41 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-28 | Janssen Biotech, Inc. | $39 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-28 | Janssen Biotech, Inc. | $22 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-27 | Janssen Biotech, Inc. | $758 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-06-27 | Janssen Biotech, Inc. | $312 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-06-27 | Janssen Biotech, Inc. | $226 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-06-27 | Janssen Biotech, Inc. | $127 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-27 | Janssen Biotech, Inc. | $16 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-23 | ARGENX US, INC. | $4,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-06-23 | ARGENX US, INC. | $43 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-06-23 | ARGENX US, INC. | $19 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-06-23 | ARGENX US, INC. | $15 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2025 | |
| 2025-06-20 | ABBVIE INC. | $231 | Travel and Lodging | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-06-20 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-06-18 | ARGENX US, INC. | $93 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2025 | |
| 2025-06-18 | GENZYME CORPORATION | $21 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-12 | Alexion Pharmaceuticals, Inc. | $3,120 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-06-11 | Lundbeck LLC | $19 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2025 | |
| 2025-06-10 | ARGENX US, INC. | $536 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-06-10 | ARGENX US, INC. | $144 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2025 | |
| 2025-06-10 | ARGENX US, INC. | $40 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-06-09 | ARGENX US, INC. | $4,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-06-09 | ARGENX US, INC. | $583 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-06-09 | ARGENX US, INC. | $267 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-06-09 | ARGENX US, INC. | $66 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2025 | |
| 2025-06-07 | Amgen Inc. | $115 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-06-06 | Amgen Inc. | $792 | Travel and Lodging | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-06-06 | Amgen Inc. | $155 | Travel and Lodging | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-06-06 | Amgen Inc. | $109 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-06-06 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-06-05 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-06-04 | ARGENX US, INC. | $394 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-06-04 | ARGENX US, INC. | $353 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-06-04 | ARGENX US, INC. | $253 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-06-04 | ARGENX US, INC. | $125 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2025 | |
| 2025-06-04 | ARGENX US, INC. | $55 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-06-04 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-06-04 | ARGENX US, INC. | $20 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-05-30 | ARGENX US, INC. | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-05-29 | Alexion Pharmaceuticals, Inc. | $27 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-05-29 | Janssen Scientific Affairs, LLC | $18 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-23 | TG Therapeutics, Inc. | $31 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 |
The latest 200 records of 1,467.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-07-30 | GENZYME CORPORATION | Springfield Pc | $16,300 | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2025 |
| 2024-01-23 | Alexion Pharmaceuticals, Inc. | NEUROLOGY ASSOC OF EUGENE SPRINGFIELD PC | $12,092 | A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN205 | 2024 |
| 2023-02-01 | Alexion Pharmaceuticals, Inc. | NEUROLOGY ASSOC OF EUGENE SPRINGFIELD PC | $26,192 | A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN205 | 2023 |
| 2022-11-10 | Alexion Pharmaceuticals, Inc. | NEUROLOGY ASSOC OF EUGENE SPRINGFIELD PC | $800 | Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Co | 2022 |
| 2021-12-31 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-11-30 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-10-29 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-09-30 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-08-31 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-07-30 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-07-07 | EMD Serono, Inc. | Neurology Associates of Eugene/Springfield PC | $29 | A Phase III, Multicenter, Randomized, ParallelGroup, Double Blind, Double Dummy, ActiveControlled Study of Evobrutinib C | 2021 |
| 2021-07-07 | EMD Serono, Inc. | Neurology Associates of Eugene/Springfield PC | $600 | A Phase III, Multicenter, Randomized, ParallelGroup, Double Blind, Double Dummy, ActiveControlled Study of Evobrutinib C | 2021 |
| 2021-06-30 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-05-31 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-04-30 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-03-31 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-03-18 | Alexion Pharmaceuticals, Inc. | Neurology Associates Eugene-Springfield PC (Oregon Neurology) | $3,000 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravuli | 2021 |
| 2021-02-26 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-02-25 | Alexion Pharmaceuticals, Inc. | Neurology Associates Eugene-Springfield PC (Oregon Neurology) | $7,000 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravuli | 2021 |
| 2021-01-29 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2020-12-31 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-11-30 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-10-30 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-09-30 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-08-31 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-08-06 | EMD Serono, Inc. | Neurology Associates of Eugene/Springfield PC | $1,500 | A Phase III, Multicenter, Randomized, ParallelGroup, Double Blind, Double Dummy, ActiveControlled Study of Evobrutinib C | 2020 |
| 2020-08-06 | EMD Serono, Inc. | Neurology Associates of Eugene/Springfield PC | $10,000 | A Phase III, Multicenter, Randomized, ParallelGroup, Double Blind, Double Dummy, ActiveControlled Study of Evobrutinib C | 2020 |
| 2020-08-06 | EMD Serono, Inc. | Neurology Associates of Eugene/Springfield PC | $2,000 | A Phase III, Multicenter, Randomized, ParallelGroup, Double Blind, Double Dummy, ActiveControlled Study of Evobrutinib C | 2020 |
| 2020-08-06 | EMD Serono, Inc. | Neurology Associates of Eugene/Springfield PC | $800 | A Phase III, Multicenter, Randomized, ParallelGroup, Double Blind, Double Dummy, ActiveControlled Study of Evobrutinib C | 2020 |
| 2020-07-31 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-06-30 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-05-29 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-04-30 | EMD Serono, Inc. | Oregon Neurology | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-01-21 | EMD Serono, Inc. | Neurology Associates of Eugene/Springfield PC | $1,500 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-01-21 | EMD Serono, Inc. | Neurology Associates of Eugene/Springfield PC | $4,614 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-01-21 | EMD Serono, Inc. | Neurology Associates of Eugene/Springfield PC | $800 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-01-21 | EMD Serono, Inc. | Neurology Associates of Eugene/Springfield PC | $1,000 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Springfield, OR, county Lane County, OR, state Oregon; placed by its city name.
| Measure | Place (city or town) Springfield, OR | County Lane County, OR | State Oregon |
|---|---|---|---|
| Population B01003 | 61,499 | 384,207 | 4,254,293 |
| Population, 2020 census P1 | 61,851 | 382,971 | 4,237,256 |
| Median age B01002 | 37.4 | 40.3 | 40.4 |
| Under 18 B01001 | 21.0% | 17.5% | 19.9% |
| 65 and over B01001 | 16.3% | 20.8% | 19.1% |
| Households B11001 | 25,210 | 160,445 | 1,718,422 |
| Foreign born B05002 | 5.9% | 5.4% | 9.8% |
| Median household income B19013 | $68,761 | $71,544 | $83,011 |
| Median family income B19113 | $75,471 | $90,167 | $102,281 |
| Per capita income B19301 | $32,388 | $39,088 | $45,612 |
| Poverty rate B17001 | 14.9% | 15.3% | 11.9% |
| Unemployment rate B23025 | 5.1% | 6.4% | 5.4% |
| Civilian labor force B23025 | 33,041 | 195,670 | 2,183,462 |
| Mean commute (minutes) B08013 | 19.4 | 20.2 | 23.0 |
| Bachelor's degree or higher B15003 | 22.4% | 34.0% | 36.8% |
| Housing units B25001 | 25,905 | 169,788 | 1,857,992 |
| Owner-occupied B25003 | 55.0% | 59.7% | 63.3% |
| Renters B25003 | 45.0% | 40.3% | 36.7% |
| Median home value B25077 | $358,700 | $430,600 | $477,600 |
| Median gross rent B25064 | $1,258 | $1,355 | $1,525 |
| White, not Hispanic B03002 | 74.8% | 78.2% | 71.4% |
| Black B03002 | 0.9% | 1.1% | 1.8% |
| Hispanic or Latino B03002 | 15.1% | 10.5% | 14.7% |
| Asian B03002 | 1.5% | 2.5% | 4.4% |
| American Indian and Alaska Native B03002 | 1.1% | 0.7% | 0.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Springfield, OR.
Comments